| | | From Google:
Triera's aptamer platform is protected by multiple patents, primarily through an exclusive license agreement with
McMaster University, which covers the use of aptamers and DNAzymes developed by the university's Li Lab. Zentek (Triera's parent company) has also filed its own provisional patents to protect innovations to the platform, such as improvements for manufacturing and high-binding affinity aptamers. The company continues to expand its patent portfolio for its discoveries.
Core intellectual property
- Licensing agreement: Triera holds a 20-year, worldwide, exclusive license from McMaster University to practice aptamer and DNAzyme technologies developed by the Li Lab.
- Scope: The license agreement has been amended to cover all aptamer and DNAzyme uses, including diagnostics, therapeutics, and neutralization agents.
Zentek's own patents
- Provisional patents: Zentek has filed provisional patents to protect its innovations, including upgrades to the platform that have improved binding affinity and solved manufacturing challenges.
- Manufacturing improvements: One patent application specifically covers innovations that have resulted in high-binding affinity (HBA) aptamers being produced with approximately a
95%
95%
yield, which addresses a major roadblock for commercial products. - Ongoing development: The company continues to build on its patent portfolio as it makes new discoveries and innovations.
|
|
